{"url_path":"/sec/allo/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1737287/0001628280-26-034585-index.html","accession_number":"0001628280-26-034585","cik":"0001737287","ticker":"ALLO","issuer_name":"Allogene Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737287/0001628280-26-034585-index.html","primary_entity_key":"0001737287","primary_entity_name":"Allogene Therapeutics, Inc."},"word_count":60,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings\n\nFrom time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows."}